CU Department of Ophthalmology Professor Prem Subramanian, MD, PhD, discusses a double-masked randomized placebo controlled trial of the use of TEPEZZA in patients with a much longer duration of thyroid eye disease than those who are enrolled in the phase 2 and phase 3 studies that lead to FDA approval.